|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Al-Bahlani S, Al-Lawati H, Al-Adawi M,
Al-Abri N, Al-Dhahli B and Al-Adawi K: Fatty acid synthase
regulates the chemosensitivity of breast cancer cells to
cisplatin-induced apoptosis. Apoptosis. 22:865–876. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scolnick DM and Halazonetis TD: Chfr
defines a mitotic stress checkpoint that delays entry into
metaphase. Nature. 406:430–435. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ding Y, Lian HF and Du Y:
Clinicopathological significance of CHFR promoter
methylation in gastric cancer: A meta-analysis. Oncotarget.
9:10083–10090. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mizuno K, Osada H, Konishi H, Tatematsu Y,
Yatabe Y, Mitsudomi T, Fujii Y and Takahashi T: Aberrant
hypermethylation of the CHFR prophase checkpoint gene in human lung
cancers. Oncogene. 21:2328–2333. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shibata Y, Haruki N, Kuwabara Y, Ishiguro
H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, et
al: Chfr expression is downregulated by CpG island hypermethylation
in esophageal cancer. Carcinogenesis. 23:1695–1699. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glinsky GV, Berezovska O and Glinskii AB:
Microarray analysis identifies a death-from-cancer signature
predicting therapy failure in patients with multiple types of
cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tokunaga E, Oki E, Nishida K, Koga T,
Yoshida R, Ikeda K, Kojima A, Egashira A, Morita M, Kakeji Y and
Maehara Y: Aberrant hypermethylation of the promoter region of the
CHFR gene is rare in primary breast cancer. Breast Cancer Res
Treat. 97:199–203. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vanharanta S and Massague J: Origins of
metastatic traits. Cancer Cell. 24:410–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng H, Shen M, Zha YL, Li W, Wei Y,
Blanco MA, Ren G, Zhou T, Storz P, Wang HY and Kang Y: PKD1
phosphorylation-dependent degradation of SNAIL by SCF-FBXO11
regulates epithelial-mesenchymal transition and metastasis. Cancer
Cell. 26:358–373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kashima L, Idogawa M, Mita H, Shitashige
M, Yamada T, Ogi K, Suzuki H, Toyota M, Ariga H, Sasaki Y and
Tokino T: CHFR protein regulates mitotic checkpoint by targeting
PARP-1 protein for ubiquitination and degradation. J Biol Chem.
287:12975–12984. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Derks S, Cleven AH, Melotte V, Smits KM,
Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG and
van Engeland M: Emerging evidence for CHFR as a cancer biomarker:
from tumor biology to precision medicine. Cancer Metastasis Rev.
33:161–171. 2014.PubMed/NCBI
|
|
17
|
Kawasaki T, Ohnishi M, Nosho K, Suemoto Y,
Kirkner GJ, Meyerhardt JA, Fuchs CS and Ogino S: CpG island
methylator phenotype-low (CIMP-low) colorectal cancer shows not
only few methylated CIMP-high-specific CpG islands, but also
low-level methylation at individual loci. Mod Pathol. 21:245–255.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Soutto M, Peng D, Razvi M, Ruemmele P,
Hartmann A, Roessner A, Schneider-Stock R and El-Rifai W:
Epigenetic and genetic silencing of CHFR in esophageal
adenocarcinomas. Cancer. 116:4033–4042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pillai RN, Brodie SA, Sica GL, Shaojin Y,
Li G, Nickleach DC, Yuan L, Varma VA, Bonta D, Herman JG, et al:
CHFR protein expression predicts outcomes to taxane-based first
line therapy in metastatic NSCLC. Clin Cancer Res. 19:1603–1611.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao L, Liu F, Zhang H, Sun J and Ma Y:
CHFR hypermethylation, a frequent event in acute myeloid leukemia,
is independently associated with an adverse outcome. Genes
Chromosomes Cancer. 55:158–168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He MY, Rancoule C, Rehailia-Blanchard A,
Espenel S, Trone JC, Bernichon E, Guillaume E, Vallard A and Magné
N: Radiotherapy in triple-negative breast cancer: Current situation
and upcoming strategies. Crit Rev Oncol Hematol. 131:96–101. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khaled N and Bidet Y: New insights into
the implication of epigenetic alterations in the EMT of triple
negative breast cancer. Cancers (Basel). 11:5592019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Neelakantan D, Zhou H, Oliphant MUJ, Zhang
X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, et
al: EMT cells increase breast cancer metastasis via paracrine GLI
activation in neighbouring tumour cells. Nat Commun. 8:157732017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: Emt: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hinz S and LaBarge MA: Hijacking EMT:
Better fat than dead. Cancer Cell. 35:1–2. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang S, He F, Dai M, Pan J, Wang J and Ye
B: CHFR promotes the migration of human gastric cancer cells by
inducing epithelial-to-mesenchymal transition in a HDAC1-dependent
manner. OncoTargets Ther. 12:1075–1084. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Privette LM, González ME, Ding L, Kleer CG
and Petty EM: Altered expression of the early mitotic checkpoint
protein, CHFR, in breast cancers: Implications for tumor
suppression. Cancer Res. 13:6064–6074. 2007. View Article : Google Scholar : PubMed/NCBI
|
